

DABIGATRAN MODULE

For Safe and Efficient Management of New Oral Anticoagulants

The Dabigatran Module integrates into the DAWN AC Anticoagulation Management Software and offers help to ensure safe prescribing and follow-up of patients on this new agent

BENEFITS:

- Enable protocol-driven care
- Record risks to the patient (thrombotic / bleeding)
- Lists of current patients treated
- Record patient education
- Shared database with existing anticoagulation records to enhance risk analysis and audit
- Track adherence and patient feedback
- Non-VKA list view for easy management of scheduled reviews
- Powerful reporting on patient outcomes and population data
- Follow protocols for Initiation, Routine Follow-up, Perioperative Actions and Compliance Checks
- Track dosing history along with side effects
- Support medical research
- Increase productivity / efficiency gains
- Increase patient safety
- Improve the consistency of dosing practices
- Ensure all information is in one place
- Integrated non-VKA history and Warfarin treatment records within the patient record
- Help to follow the recommended prescribing guidelines

Main patient screen showing questionnaire tab with list of initiation and follow-up questionnaires

The screenshot displays the patient record for Wilma White (DOB: 05/05/1955, ID: 23124234) at Blea Tarn Surgery. The interface includes a patient profile with a photo, a list of tabs (Dabigatran, Contacts, Letters, Drugs, Events, Procedures, Reviews, Reminders), and a main content area with a 'Questionnaires' tab selected. The 'Questionnaires' tab shows a message: 'Dabigatran therapy is managed using Questionnaires. To schedule a questionnaire: 1. Press the [icon] button on the Questionnaires tab to create a new questionnaire. 2. Set the due date as appropriate. 3. Press OK.' Below this is a table of questionnaires:

QuestionnaireType	Entry date	Summary
Dabigatran Follow Up	30/10/2012	Scheduled
Dabigatran Follow Up	02/07/2012	CrCL not recorded - Dose: 110 mg twice daily
Dabigatran Initiation	18/06/2012	CrCL (mL/min): 91 - Dose: 110 mg twice daily

Additional patient details visible include: Risk class: High; Pref. clinic: Default Clinic (St Elsewhere); Phone: 015395 63091 - home; Age: 57; Diagnosis: Atrial fibrillation nonvalvular; Target Range: Non-VKA; Start date: 30/08/2012 - Indefinite (ActiveAdmitted); Anticoagulant: Dabigatran 110 mg twice daily; Treatment Plan: 1 of 1 ActiveAdmitted; Risks: h/o dyspepsia, hypothyroid. A note at the bottom states: 'St Elsewhere - Support Dawn 11/09/2012 15:17 Wilma's sister phoned - delayed in Portugal for another 3 weeks'.

The DAWN AC Dabigatran Module provides structured questionnaires based on the recommended use of the anticoagulant and include Initiation and Routine Follow-up. Completion of the questionnaires can be scheduled for future dates so that the user can keep track of patients who have started on Dabigatran or are due for a change to Dabigatran (see reference below for recommendations that DAWN AC supports).

The questionnaires cover:

- Patient characteristics e.g. age, weight, history
- Indications and risk factors for Dabigatran therapy
- Renal function, including a calculator for Cockcroft-Gault estimate of CrCl
- Records for liver function or other tests
- Contraindicated or interacting drugs including other anticoagulants or platelet inhibitors
- A reminder to ensure INR is not 2 or above if switching from a vitamin K antagonist
- Contraindicated conditions and haemorrhagic risks
- Records for CHA₂DS₂VASc and HASBLED scores
- Notes for planned procedures and other comments
- Dabigatran dose

Agno W, Crowther M, Baglin T, Falango A, Buller H, Palareti G. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis 2013; 11: 177-9

Sample screenshots from the Dabigatran module

First part of initiation questionnaire

Questionnaire showing contraindicated and interacting drugs

Questionnaire showing dose warning

Dosing regime	Advice
Dabigatran 150 mg Twice Daily	Normal dose
Dabigatran 110 mg Twice Daily	Patients aged 80 or over, or at risk of bleeding